Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,411.87
(
0.15%
)
US TECH 100
28,435.20
(
0.51%
)
Dow Jones
49,510.76
(
-0.50%
)
Brent Oil
105.31
(
-0.43%
)
Bitcoin
79,319.42
(
-1.46%
)
News Focus
News Focus
Post# of 6105
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122973
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: wags23 post# 6084

Thursday, 04/30/2026 11:34:19 AM

Thursday, April 30, 2026 11:34:19 AM

Post# of 6105
The '937 patent covers pibrentasvir, the NS5A-inhibitor constituent of Mavyret that was developed by ABBV itself. Hence, I don't think the '937 patent is relevant to ENTA's royalty steams from Mavyret since ABBV did not license this patent from ENTA.

OTOH, the '807 (glecaprevir) patent I cited in my previous post is eligible for a pediatric extension, which would extend protection by six months to June 2036.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent ENTA News
More ENTA News